Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.56 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.54 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.53 |
| ▸ | CTSB | P07858 | 2/20 | 0.53 |
| ▸ | GLP1R | P43220 | 6/20 | 0.52 |
| ▸ | GIPR | P48546 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29707524 | 0.99 | C5AR1 (0.56) | C5AR1IL23RTACR1CXCL8CXCR4 | |
| SCHEMBL29707518 | 0.97 | C5AR1 (0.61) | C5AR1IL23RTACR1CXCR4GLP1R | |
| SCHEMBL31119411 | 0.97 | C5AR1 (0.61) | C5AR1IL23RTACR1CXCR4GLP1R | |
| SCHEMBL29707516 | 0.94 | C5AR1 (0.61) | C5AR1IL23RTACR1CXCR4GLP1R | |
| SCHEMBL29707517 | 0.93 | C5AR1 (0.61) | C5AR1IL23RTACR1CXCR4GLP1R | |
| SCHEMBL30168658 | 0.85 | GLP1R (0.61) | CXCL8GLP1RGIPR | |
| SCHEMBL30567724 | 0.85 | CXCL8 (0.58) | C5AR1IL23RCXCL8CXCR4 | |
| SCHEMBL30608611 | 0.85 | CAPN1 (0.50) | C5AR1CXCL8CXCR4CAPN1CTSB | |
| SCHEMBL30608621 | 0.85 | CAPN1 (0.50) | C5AR1CXCL8CXCR4CAPN1CTSB | |
| SCHEMBL31357810 | 0.84 | DPP3 (0.57) | IL23RTACR1CAPN1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299566-A1 | POLY-ARGININE DERIVATIVES FOR ENHANCING BRAIN-DERIVED GROWTH FACTOR TO MITIGATE NEUROLOGICAL DISORDERS | BROWN UNIVERSITY | 2024-09-12 | — | — | US | disclosed |
| WO-2022150362-A1 | POLY-ARGININE DERIVATIVES FOR ENHANCING BRAIN-DERIVED GROWTH FACTOR TO MITIGATE NEUROLOGICAL DISORDERS | MARSHALL JOHN (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299566-A1 | POLY-ARGININE DERIVATIVES FOR ENHANCING BRAIN-DERIVED GROWTH FACTOR TO MITIGATE NEUROLOGICAL DISORDERS | PSD, BDNF, ARGLU1 | C5AR1 3791/4885IL23R 2128/4885TACR1 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.